Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR)

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $53.00 price target on Kymera Therapeutics (NASDAQ: KYMR).

The analyst commented, "Following 4Q EPS call, we came away w/ continued conviction in Kymera's platform/pipeline & mgmt ability to execute on ongoing programs. We see 2025 as a pivotal year with multiple milestones including data readouts expected (catalysts below). Majority of the focus on the call was around STAT-6 degrader KT-621, upcoming Ph1 readout expected in June 2025, and strategy to move forward including plans for Ph1b initiation in AD in 2Q25, Ph1b readout in 4Q25, to be followed by Ph2 initiation. KYMR has $851M in cash with runway into mid-2027, per mgmt; we expect readouts through 2025 to continue to increase investor confidence. Reiterate Buy. "

For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.

Shares of Kymera Therapeutics closed at $30.25 yesterday.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold
• JPMorgan Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral